Sr Director, Global Translational Sciences Lead, Molecular Imaging

At Bayer we’re visionaries, driven to solve the world’s toughest challenges and striving for a world where 'Health for all Hunger for none’ is no longer a dream, but a real possibility. We’re doing it with energy, curiosity and sheer dedication, always learning from unique perspectives of those around us, expanding our thinking, growing our capabilities and redefining ‘impossible’. There are so many reasons to join us. If you’re hungry to build a varied and meaningful career in a community of brilliant and diverse minds to make a real difference, there’s only one choice.

Sr Director, Global Translational Sciences Lead, Molecular Imaging 

The Senior Director, Global Translational Sciences Lead, Molecular Imaging is responsible for driving the development of translational and biomarker objectives for preclinical and early clinical strategies in support of Bayer Radiology Nuclear Medicine diagnostic radiotracer assets. In this role, you will focus on innovating and adding value to patients by differentiating radiopharmaceuticals for use as targeted diagnostics and/or therapeutics and driving translational understanding of clinical trial data.

YOUR TASKS AND RESPONSIBILITIES
The primary responsibilities of this role, Senior Director, Global Translational Sciences Lead Molecular Imaging, are to:

• Ensure effective collaborations between preclinical research and clinical development, establishing strong target-to-disease connections for radiotracers as standalone diagnostics or in co-development with targeted radiotherapies (TRTs) or other therapeutics;
• Integrate and validate technical knowledge of radiopharmaceuticals’ mechanisms of action and identification of imaging biomarkers in preclinical development into strategies for the clinical development of diagnostic assets;
• Develop the overall early clinical development strategy of radiotracer assets in co-creation with relevant thought-leader communities, vendors, and partners with a central customer/patient value approach;
• Develop and oversee clinical trial designs (First in Human to Phase 2a) for radiotracer assets, in collaboration with vendors and partners;
• Lead the matrix-management of clinical trial teams, collaborating across the organization and externally with service providers/investigator sites;
• Lead all aspects of translational studies and deliverables with CROs and collaborators to support new and ongoing clinical studies;
• Provide technical expertise as required for the development, troubleshooting, and tech transfer of manufacturing methods to external vendors/partners;
• Support the development of cGLP and cGMP radiopharmaceutical manufacturing processes to enable clinical development activities;
• Review experimental data both internally and from external vendors/partners, analyze, summarize, and interpret results, and relay findings to stakeholders, internal and external (including representing Bayer at regulatory meetings) through summary reports, technical documents, or presentations;
• Author/co-author pre-clinical and clinical documents as applicable, such as IBs, protocols, study reports, statistical analysis plans, publications, and regulatory submissions;
• Support optimization of standard methodologies in clinical trial operations and adopt an open learning and sharing environment, optimizing methodologies and utilizing digital tools in clinical trials;
• May support and contribute to Business Development & Licensing (BD&L) activities;
• Mentor colleagues and promote knowledge-sharing.
• The primary location for this role is Whippany, NJ. Residence-based candidates located in the US and willing to travel may also be considered for this role.

WHO YOU ARE
Bayer seeks an incumbent who possesses the following:

Required Qualifications:

• Minimum of a Master's Degree, MD, PharmD, or PhD in Molecular Imaging/Nuclear Medicine or a related field;
• At least 10 years of experience in the Pharma Industry, with 5 or more years in Translational Science/Medicine and/or Early Clinical Development (Phase 1-2a) of Radiopharmaceuticals, preferably in diagnostic radiotracers;
• A track record of clinical trial management/operations of Radiopharmaceuticals and broad knowledge of the drug development field, including experience leading CROs for translational studies and biomarkers for clinical trials;
• Proven experience with FDA regulatory requirements and ICH GCP guidelines for the development of radiopharmaceuticals, preferably diagnostic radiotracers (IND submission, FDA formal meetings, etc.). Experience with other international health authorities will be valued;
• Proven understanding/expertise of radiopharmaceutical mechanis